Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.1% – Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares rose 7.1% during trading on Monday . The stock traded as high as $33.14 and last traded at $33.1150. Approximately 264,654 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 1,265,975 shares. The stock had previously closed at $30.91.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. B. Riley Financial upped their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Wall Street Zen lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Piper Sandler restated an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a report on Tuesday, March 10th. Finally, Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $46.09.

Capricor Therapeutics Trading Up 8.4%

The firm’s fifty day moving average price is $31.11 and its 200-day moving average price is $22.76. The company has a market cap of $1.94 billion, a P/E ratio of -14.82 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, research analysts forecast that Capricor Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Capricor Therapeutics news, Director Karimah Es Sabar sold 7,529 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the sale, the director owned 7,529 shares in the company, valued at approximately $240,928. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $31.70, for a total value of $792,500.00. Following the sale, the chief financial officer directly owned 8,223 shares in the company, valued at $260,669.10. The trade was a 75.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 172,529 shares of company stock valued at $5,302,440 in the last quarter. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CAPR. Vanguard Group Inc. raised its stake in shares of Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after buying an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $51,533,000. Tang Capital Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at about $49,062,000. RA Capital Management L.P. bought a new stake in Capricor Therapeutics in the fourth quarter valued at about $43,516,000. Finally, Geode Capital Management LLC raised its position in Capricor Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after purchasing an additional 55,766 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.